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Background. The goal of this study was to determine whether leukemia inhibitory factor (LIF) promotes anti-inflammatory activity
after stroke in a sex-dependent manner. Methods. Aged (18-month-old) Sprague-Dawley rats of both sexes underwent sham
surgery or permanent middle cerebral artery occlusion (MCAO). Animals received three doses of intravenous LIF (125 μg/kg)
or PBS at 6, 24, and 48 h before euthanization at 72 h. Spleen weights were measured immediately following euthanization.
Western blot was used to measure protein levels of CCL8, CD11b, CXCL9, CXCL10, IL-12 p40, IL-3, and the LIF receptor
(LIFR) in spleen tissue. ELISA was used to measure IL-1β, IL-6, TNFα, and IFNγ in spleen tissue. A Griess Assay was used to
indirectly quantify NO levels via measurement of nitrite. Levels of cellular markers and inflammatory mediators were
normalized to the baseline (sham) group from each sex. Statistical analysis was performed using two-way ANOVA and followed
by Fisher’s LSD post hoc test. Results. Aged female rats showed a significantly lower spleen weight after MCAO, but showed a
significant increase in spleen size after LIF treatment. This effect was observed in aged male rats, but not to as great of an extent.
CD11b levels were significantly higher in the spleens of MCAO+PBS males compared to their female counterparts, but there
was no significant difference in CD11b levels between MCAO+LIF males and females. LIF significantly increased CXCL9 after
LIF treatment in aged male and female rats. LIFR and IL-3 were upregulated after LIF treatment in aged females. Splenic nitrate
increased after MCAO but decreased after LIF treatment in aged females. Splenic nitrate levels did not increase after MCAO but
did increase after LIF treatment in aged males. The following cytokines/chemokines were not altered by sex or treatment: TNFα,
IL-6, IL-12 p40, CCL8, IFNγ, and CXCL10. Conclusions. LIF treatment after permanent MCAO induces sex-dependent effects
on the poststroke splenic response and the production of proinflammatory cytokines among aged rats.
1. Introduction
Ischemic stroke is currently the fifth leading cause of death in
the United States and one of the leading causes of adult dis-
ability. The most damaging type of stroke, an emergent large
vessel occlusion (ELVO) occurs when a thrombus blocks
flow to one of the brain’s major arteries [1]. While intrave-
nous tissue plasminogen activator (tPA) is effective at treat-
ing small-vessel strokes, it is often ineffective at restoring
blood flow during an ELVO [2–4]. ELVO patients may
undergo endovascular thrombectomy (EVT), in which a
stent retriever is used to retrieve the thrombus from the
occluded vessel, up to 24 h after the patient’s last known nor-
mal [5]. Patients who are ineligible for EVT are extremely
limited concerning their treatment options. Furthermore,
the prognosis for ELVO without recanalization is extremely
dismal; most patients are at risk of death or left with severe
deficits in sensorimotor skills and cognition [6].
While acute energy failure is responsible for the initial
phase of neuronal death, the majority of tissue damage
occurs hours to days after the onset of stroke [7, 8]. Microglia
activated by substances released from dying neurons
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produce proinflammatory mediators that compromise the
blood-brain barrier [9–13]. During this period, increased
adrenergic signaling in splenic nerves promotes contrac-
tion of the spleen and release of splenocyte populations
into the peripheral circulation [14–18]. The breakdown
of the blood-brain barrier usually coincides with the pro-
duction of matrix metalloproteinases by activated microg-
lia [10, 19, 20]. Splenocytes infiltrate the ischemic tissue
and further perpetuate the inflammatory cascade through
the subsequent release of inflammatory mediators and
reactive oxygen species [21]. This poststroke splenic
response has been observed in human stroke patients in
addition to rodents [22].
Interferon-gamma (IFNγ), a proinflammatory cytokine
produced by CD4+ T cells, CD8+ T cells, and NK cells, is
largely responsible for initiating the peripheral immune
response after stroke [23, 24]. Upon stimulation with proin-
flammatory cytokines such as IL-2 and IL-12, T cells release
IFNγ, which stimulates the production of CXCL10 in
monocytes/macrophages and microglia [25–28]. Offner
et al. showed that several proinflammatory chemokines,
including CXCL10, are upregulated 22 h after stroke [29].
CXCL10, which increases intracellular calcium through
binding to CXCR3, promotes chemotaxis of T cells and
other peripheral leukocytes towards the site of injury [30–
32]. Administration of antibodies to block the
IFNγ/CXCL10 signaling yields a significant decrease in the
infarct volume and prevents the reduction in spleen size at
72 h after stroke [24]. Furthermore, blocking this signaling
pathway significantly reduced the poststroke infiltration of
immune response into the brain [23, 24].
Leukemia inhibitory factor (LIF), a cytokine in the IL-
6 family, has shown efficacy in promoting cellular survival
and countering peripheral inflammation when adminis-
tered intravenously after permanent stroke [33–37]. LIF
activates several signaling pathways, including the
PI3K/Akt signaling cascade, which promotes the upregula-
tion of antioxidant enzymes including metallothionein III
and peroxiredoxin IV in oligodendrocytes and superoxide
dismutase 3 in neurons [34, 35]. Also, LIF treatment pro-
motes anti-inflammatory signaling by decreasing splenic
levels of IFNγ and preventing the upregulation of CXCL10
that occurs after stroke [36]. However, these studies were
performed in 3-month-old male rats, which are equivalent
age-wise to adolescent male humans. Considering that the
risk of stroke doubles with every decade after the age of
55, the use of young animals of one sex to mimic human
stroke patients is not an optimal model.
Recently, this group demonstrated that administration of
LIF at 6, 24, and 48 h after MCAO promotes partial motor
skill recovery in aged female rats, but does not significantly
decrease tissue damage [38]. This phenomenon is attributed
to the significantly lower levels of LIFR in the brain tissue
of aged males and females compared to young male rats.
However, very little is known about the role of the aged
immune system in poststroke pathophysiology. This manu-
script explores how LIF treatment modulates the splenic
inflammatory response after stroke in an age-dependent
and sex-dependent manner.
2. Materials and Methods
Retired breeding pairs of Sprague-Dawley rats (9-10mo.)
were purchased from Envigo (Indianapolis, IN) and housed
until they reached the age of 18-19mo. All animals were kept
in a climate-controlled room and allowed access to food and
water ad libitum. Animals were kept on a 12h light/dark
cycle (07:00–19:00 h). All animals were randomly assigned
to treatment groups before surgical procedures, and sample
sizes were calculated using StatMate software (GraphPad,
San Diego, CA). All procedures were approved according to
the University of Kentucky Institutional Animal Care and
Use Committee.
2.1. Middle Cerebral Artery Occlusion. Permanent focal cere-
bral ischemia was induced using the intraluminal middle
cerebral artery occlusion (MCAO) model as previously
described [39]. A 40mm monofilament was introduced
through the ligated external carotid artery and advanced
through the internal carotid artery. The filament was
advanced until it reached the origin of the middle cerebral
artery. Animals subjected to the sham MCAO procedure
were anesthetized and underwent exposure of the common
carotid artery without subsequent occlusion of the middle
cerebral artery.
2.2. Drug Treatment. All animals were treated prophylacti-
cally with ketoprofen (10mg/kg s.c.) and atropine
(0.25mg/kg s.c.) with two additional doses of ketoprofen at
24 and 48 h post-MCAO. Recombinant human LIF (ProSpec,
Ness Ziona, Israel) (125μg/kg) or PBS (pH7.4) was adminis-
tered intravenously at 6, 24, and 48 h post-MCAO as previ-
ously described [34, 35]. Animals were randomly assigned
to treatment groups, and all lab personnel administering
drugs were blinded to treatments.
2.3. Tissue Collection. Rats were euthanized at 72h post-
MCAO via intraperitoneal injection of ketamine/xylazine
solution (75mg/kg and 7.5mg/kg) [23]. Spleens were col-
lected immediately before perfusion. Animals used for bio-
chemical analysis were perfused with saline before
obtaining tissue.
2.4. Tissue Homogenization. To obtain whole-cell extracts,
frozen tissue was homogenized in a whole-cell lysis buffer
containing the following: 50mM Tris pH8, 150mM NaCl,
0.1% SDS, 1% IGEPAL, 1mM PMSF, and a complete Mini
protease inhibitor cocktail (Roche Diagnostics, Indianapolis,
IN). An electric homogenizer was used to disrupt tissue, and
lysates were incubated on ice for 20min. Tissue lysates were
vortexed and pipetted to break up nuclei. Protein concentra-
tions were determined by performing a Bradford Assay
according to the manufacturer’s protocol (Bio-Rad, Hercules,
CA). Briefly, a Bradford reagent containing Coomassie blue
was added to the diluted protein samples, and absorbance
was read at 595nm using a SmartSpec 3000 spectrophotom-
eter (Bio-Rad). Concentrations were determined by compar-
ing the absorbance readings against a standard curve.
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2.5. Western Blot. Western blot analysis was used for semi-
quantitative measurement of protein expression using a pre-
viously described procedure [35]. Briefly, whole-cell lysates
from spleen tissue were run on SDS-PAGE gels and trans-
ferred to nitrocellulose membranes. Membranes were
blocked with 5% nonfat milk in TBS and probed with the fol-
lowing antibodies: rabbit anti-LIFR (C-19) (1 : 100; Santa
Cruz Biotechnology, Dallas, TX, US), rabbit anti-IL-12 p40
(1 : 100; ABBiotech, San Diego, CA), rabbit anti-CXCL10
(1 : 5000; Abcam, San Francisco, US), rabbit anti-IL-3 (R&D
Biosystems; Minneapolis, MN), rabbit anti-CXCL9
(1 : 1000; Fitzgerald Industries Int., North Action, MA),
rabbit-anti-CCL8 (1 : 500; Biorbyt, Cambridge, UK), and
mouse anti-CD11b (1 : 1000; Abcam). Membranes were
incubated in IRDye 800CW goat anti-rabbit antibodies
(1 : 20,000; Li-Cor) for the detection of protein bands. Mem-
branes were visualized using the Odyssey CLx Imaging Sys-
tem (Li-Cor). To normalize for loading, membranes
containing whole-cell extracts were reprobed with mouse
anti-β-actin (1 : 5000; Novus Biologicals) and IRDye 680RD
goat anti-mouse antibodies (1 : 20,000; Li-Cor). Western blot
bands were quantified using ImageJ software (NIH,
Bethesda, MD).
2.6. Griess Assay. For indirect measurement of NO produc-
tion, a Griess Assay Kit (Molecular Probes, Eugene, OR),
was used to measure nitrite (NO2
-) levels in the spleen tissue
from aged rats. The assay was performed according to the
manufacturer’s protocol. The concentration of NO2
- in each
spleen sample was normalized to the protein concentration
and expressed in terms of % baseline (sham) levels.
2.7. ELISA. To measure the release of IFNγ, TNFα, IL-1β, IL-
6, and IL-10 in spleen tissue, ELISA was performed as previ-
ously described according to the manufacturer’s protocol
using the appropriate DuoSet ELISA kits (R&D Systems,
Inc., Minneapolis, MN). The concentration of the cytokine
in each spleen sample was normalized to the protein concen-
tration and expressed in terms of % baseline (sham) levels.
2.8. Data Analysis. All data are expressed as the mean ± the
standard error of the mean. All data from treatment groups
were normalized to the mean of the respective sham group
from each sex. Statistical analysis was performed using
GraphPad Prism 8.4.3. Software (La Jolla, CA). Data were
analyzed using a two-way ANOVA followed by Fisher’s pro-
tected LSD post hoc test to determine statistical significance.
If a significant interaction was found within the two-way
ANOVA, individual differences were determined using Fish-
er’s protected LSD post hoc test. A p-value of less than 0.05
was considered statistically significant. All reported p-values
are two-tailed.
3. Results
3.1. LIF Treatment Increases Spleen Weight after MCAO in
Aged Animals. Spleen weights were measured immediately
following euthanization at 72 h after MCAO and normalized
to the mean spleen weight from aged male and aged female
rats. There was a significant effect of drug treatment on
spleen weight (F2,83 = 38:07; p < 0:0001) as well as a signifi-
cant interaction between sex and treatment (F2,83 = 10:71; p
< 0:0001). While there was a significant decrease in spleen
size among female MCAO+PBS rats compared to sham
females (p < 0:001), the MCAO+LIF females had signifi-
cantly larger spleens than the MCAO+PBS females
(p < 0:0001) and sham females (p < 0:001). MCAO+PBS
males did not show significant changes in spleen size com-
pared to their sham counterparts, but MCAO+LIF males
had significantly larger spleens compared to their MCAO
+PBS counterparts (p < 0:01). Furthermore, while MCAO
+PBS females showed a significantly larger decrease in spleen
weight compared to their male counterparts (p < 0:05), the
MCAO+LIF females showed a significantly larger increase
in spleen size after treatment compared to their male coun-
terparts (p < 0:001; Figure 1).
3.2. Sex and Treatment Affect Splenic LIFR and CD11b
Expression. Western blot was used to measure levels of LIFR
in the spleens of aged rats at 72 h after MCAO. Levels of LIFR
protein expression were normalized to respective sham levels
from each sex. There were significant effects of sex
(F1,24 = 7:931; p = 0:0096) and treatment (F1,24 = 19:79; p =
0:0002) on LIFR protein expression, as well as a significant
interaction between the two factors (F1,24 = 7:455; p =
0:0117). Spleens from LIF-treated females showed signifi-
cantly higher levels of relative LIFR expression compared to
PBS-treated animals of both sexes (p < 0:0001) and MCAO
+LIF males (p < 0:001). However, there was no significant
difference between the spleen weights from LIF-treated males
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Figure 1: LIF treatment increases spleen weight after MCAO in aged
animals. Spleen weights were measured after euthanization and
normalized to the average spleen weight for sham-operated male
(n = 9) and female animals (n = 8). The average spleen size among
LIF-treated males (n = 23) was significantly higher than that among
PBS-treated males (n = 19; ∗∗p < 0:01), but not sham males.
Although there was a significant decrease in spleen size after
MCAO among female rats (∗∗∗p < 0:001), spleens from LIF-treated
female rats were significantly larger than spleens from sham
(∗∗∗p < 0:001) and MCAO+PBS females (∗∗∗∗p < 0:0001).
Furthermore, female MCAO+PBS rats (n = 14) showed a
significantly larger decrease in spleen weight compared to PBS-
treated males (∗p < 0:05). However, LIF-treated females (n = 16)
had significantly larger spleens compared to their male counterparts
(∗∗∗p < 0:001). Male sham n = 8‐24 per treatment group.
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and PBS-treated males (Figure 2(a)). To determine levels of
CD11b in the spleen after stroke, spleen samples from ani-
mals euthanized 72h after MCAO were analyzed via western
blot. Levels of relative CD11b expression in treatment groups
were normalized to those in sham groups of the same sex.
There was a significant effect of sex on CD11b expression
(F1,12 = 11:73; p = 0:0050) and a significant interaction
between sex and treatment (F1,12 = 5:055; p = 0:0441). Rela-
tive CD11b expression was significantly lower in the
MCAO+PBS female rats compared to MCAO+PBS males
(p < 0:01) and MCAO+LIF males (p < 0:05). Furthermore,
CD11b levels were significantly higher in MCAO+PBS males
compared to MCAO+LIF females (p < 0:05). However, there
was no significant difference in CD11b levels between LIF-
treated males and females (Figure 2(b)).
3.3. Sex Affects Splenic IL-1β, but Not TNFα or IL-6. ELISA
was used to measure levels of IL-1β in spleen tissue from
aged males and females at 72 h after stroke. There was a sig-
nificant effect of treatment on IL-1β (F1,24 = 5:251; p =
0:0310), but not due to sex. IL-1β levels were significantly
higher in the spleens of MCAO+PBS females compared to
MCAO+LIF female rats (p < 0:05; Figure 3(a)). TNFα levels
in spleen tissue were also measured in the spleens of aged
male and female rats using ELISA. However, there were no
significant effects due to sex or drug treatment on splenic
TNFα levels (Figure 3(b)). IL-6 levels in splenic tissue were
also measured using ELISA; however, there were no signifi-
cant sex- or treatment-dependent alterations in IL-6 levels
(Figure 3(c)).
3.4. IL-12 p40 and CCL8 Levels Are Unchanged after MCAO
+LIF Treatment. Western blot was used to measure levels
of IL-12 p40 and CCL8 in the spleens of aged male and
female rats after MCAO and LIF treatment. There were no
significant changes in IL-12 p40 levels due to sex or drug
treatment (Figure 4(a)). Furthermore, there were no signifi-
cant effects of sex or treatment on relative CCL8 levels in
spleen tissue (Figure 4(b)).
3.5. MCAO+LIF Changes Levels of IFNγ-Inducible
Inflammatory Mediators but Not IFNγ. IFNγ levels were
measured in the spleens of aged rats using an ELISA kit.
There were no significant changes in normalized IFNγ levels
due to sex or treatment (Figure 5(a)). Nitric oxide production
was indirectly measured by detecting levels of NO2
- in spleen
tissue using a Griess Assay. The concentration of nitrite was
normalized to mMNO2
- per mg of protein, and all treatment
groups were further normalized to those of their respective
sham groups. Although the main effects of sex and treatment
on NO2
- were not significant, there was a significant interac-
tion between these two factors (F1,27 = 10:08; p = 0:0037).
The MCAO+PBS female had significantly higher levels of
NO2
- compared to male MCAO+PBS rats (p < 0:01).
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Figure 2: Sex and treatment affect splenic LIFR and CD11b expression. (a) LIFR levels in the spleens from LIF-treated females (n = 5) were
significantly higher than those in the spleens from PBS-treated females (n = 8; ∗∗p < 0:01). However, there was no significant difference
between the spleen weights from LIF-treated male rats (n = 8) and the spleen weights from PBS-treated males (n = 7). n = 3 for both sham
groups. (b) CD11b levels were significantly higher in the spleens of PBS-treated male rats (n = 4) compared to PBS-treated females (n = 4;
∗∗p < 0:01) and LIF-treated females (n = 4). However, there was was no significant difference between LIF-treated males (n = 4) and LIF-
treated females. n = 2 for both sham groups.
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However, LIF treatment significantly reduced NO2
- in female
rats compared to their MCAO+PBS counterparts (p < 0:05;
Figure 5(b)). IL-3 was measured in spleen tissue using west-
ern blot. There were significant effects due to sex
(F1,22 = 17:87; p = 0:0003) and treatment (F1,22 = 8:946; p =
0:0067). There was no difference between male and female
MCAO+PBS rats in terms of splenic IL-3. However, levels
of IL-3 in the spleens of MCAO+LIF females were signifi-
cantly higher than those of MCAO+PBS females (p < 0:01)
and MCAO+LIF male rats (p < 0:001; Figure 5(c)).
3.6. LIF Affects Splenic CXCL9, but Not CXCL10 Levels. The
IFNγ-inducible chemokines CXCL9 and CXCL10 were mea-
sured in spleen tissue using western blot. The levels of
CXCL9 in the spleen were significantly affected by treatment
(F1,11 = 19:17; p = 0:0011) but not by sex. Specifically, there
was a significant increase in CXCL9 in the spleens of
MCAO+LIF male rats compared to MCAO+PBS male rats
(p < 0:01), and the MCAO+LIF female rats had significantly
higher levels of CXCL9 compared toMCAO+PBS female rats
(p < 0:05; Figure 6(a)).
Previously, this lab demonstrated that LIF prevents the
stroke-mediated increase in splenic CXCL10 at 72 h after
stroke. However, among aged males and female rats, there
were no sex- or treatment-dependent changes in CXCL10
after MCAO and LIF treatment (Figure 6(b)).
4. Discussion
Several published studies have demonstrated that blocking
the spleen-mediated immune response can significantly
reduce the infiltration of immune cells and subsequent brain
damage after stroke [16, 17, 40]. For example, Seifert et al.
showed that administration of antibodies against IFNγ after
stroke significantly reduces tissue damage at 72h after stroke
[23, 24]. Other studies involving the administration of thera-
pies such as human umbilical cord blood cells [21, 41] and
the sigma receptor agonist 1,3-Di-o-tolylguanidine show that
blocking the splenic response is associated with positive out-
comes and reduced brain damage after MCAO.
Although the spleen weights are significantly increased
after LIF treatment in both male and female aged rats, the
results of this study indicate that female rats show a more
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Figure 3: IL-1β, but not TNFα or IL-6, is affected by sex and treatment. (a) Among LIF-treated rats, aged females (n = 5) had significantly
lower levels of IL-1β compared to their PBS-treated counterparts (n = 5; ∗p < 0:05). However, there was no difference between the relative
IL-1β expression between PBS-treated males (n = 7) and LIF-treated males (n = 11). n = 4 for both sham groups. However, (b) TNFα
levels were not significantly altered among PBS-treated males (n = 7), LIF-treated males (n = 10), PBS-treated females (n = 5), and LIF-
treated females (n = 3). n = 3 for male sham and n = 4 for female sham groups. (c) Furthermore, IL-6 levels were not significantly altered
among PBS-treated males (n = 8), LIF-treated males (n = 11), PBS-treated females (n = 6), and LIF-treated females (n = 3). n = 3 for both
sham groups.
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robust increase in spleen weight compared to their male
counterparts. A previous study by this laboratory showed
that administration of LIF at 24, 48, and 72 h after stroke
did not significantly decrease edema or cytotoxicity, although
there was a trend towards decreased brain damage among
female LIF-treated rats. However, aged female rats demon-
strated partial motor skill recovery according to two out of
the four assessments, while their male counterparts did not
show recovery according to any of the four tests. Since levels
of LIFR in the brains of aged female rats were lower than
those of aged male rats after stroke, the partial recovery
observed in aged female rats after LIF treatment may be
attributed to stronger anti-inflammatory activity [38].
Among young male rats, CD11b expression significantly
decreased after MCAO and was not affected by LIF treatment
[36]. Most likely, this pattern of expression is due to the
migration of CD11b+ cells from the spleen to the peripheral
circulation after stroke. This hypothesis is consistent with
what we observed between male and female MCAO+PBS
animals; the female animals had significantly lower levels of
relative splenic CD11b expression as well as significantly
smaller spleens compared to their male counterparts.
CD11b levels were significantly higher in the spleens of
MCAO+LIF females compared to their PBS-treated counter-
parts, which reflects the increased spleen weight observed
after LIF treatment. However, the increase in spleen size after
LIF treatment is much more pronounced than the increase in
CD11b levels, which suggests that cell surface expression of
CD11b may decrease after LIF treatment. Since CD11b sur-
face expression is an indicator of an inflammatory phenotype
[42], its downregulation would suggest anti-inflammatory
activity. Further studies using flow cytometry will be neces-
sary to confirm the specific effects of LIF on the cell surface
expression of CD11b in immune cells.
The larger increase in spleen size observed after LIF treat-
ment in female rats may also be explained by greater expres-
sion of LIFR on splenocytes seen in female rats after LIF
treatment. The upregulation of splenic LIFR could be due
to a higher number of LIFR+ cells returning to the spleen
after LIF treatment. While LIF causes an increase in spleen
size in both male and female rats, only females show an
upregulation of splenic LIFR after MCAO+LIF treatment.
These results also demonstrate that male rats show a differen-
tial response in LIFR expression between young males and
aged males; according to a previous study from our lab,
young males show decreased LIFR after LIF treatment while
aged males show no significant change in splenic LIFR levels.
However, the increase in spleen size after LIF treatment in
aged male rats might obscure any changes in the number of
LIFR+ splenocytes, since young male rats do not show a sig-
nificant change in spleen size after LIF treatment [36].
Previously, this laboratory demonstrated that LIF treat-
ment significantly reduced splenic IFN-gamma and pre-
vented the upregulation of CXCL10 after stroke [36]. Seifert
et al. demonstrated that the IFNγ/CXCL10 axis is crucial
for promoting the chemotaxis of immune cells, specifically
CD3+CD4+ Th1/Th17 and CD3+CD8+ cytotoxic T cells,
to the infarct [18, 23, 24]. Although IFNγ levels were not
changed after MCAO or LIF treatment, LIF significantly
decreased the concentration of NO2
-, which is a byproduct
of NO breakdown, in the spleens of aged female rats but
not aged male rats. Decreased NO2
- levels are likely due to
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Figure 4: Sex and treatment do not alter IL-12 p40 or CCL8. (a) There were no significant effects of sex or drug treatment on IL-12 p40 levels
in the spleens of MCAO+PBS male (n = 4) and female rats (n = 4). Furthermore, there were no significant changes in relative p40 levels after
MCAO+LIF treatment in male (n = 4) and female (n = 4) rats. n = 2 for both sham groups. (b) There were no significant effects of sex or drug
treatment on CCL8 levels in the spleens of MCAO+PBS male (n = 5) and female rats (n = 5). Furthermore, there were no significant changes
in relative p40 levels after MCAO+LIF treatment in male (n = 5) and female (n = 5) rats per treatment group. n = 4 for both sham groups.
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the changes in inducible nitric oxide synthase (iNOS) activity
and subsequent NO production [43, 44]. IFNγ released from
T cells [25] and NK cells [45] increases iNOS expression in
monocytes and neutrophils [46], which promotes NO pro-
duction and the accumulation of NO2
-. Although relative
IFNγ levels were not significantly decreased after LIF treat-
ment in female rats, iNOS expression may be mediated
together by IL-1β and IFNγ [47]. Therefore, the lower
NO2
- levels observed in spleens of female rats are attributed
to the sex-dependent effect of LIF on IL-1β production.
Sex-specific differences in the production of other proinflam-
matory cytokines such as IL-1β might be responsible for the
differential effect of LIF on IFNγ levels in the spleen. Posma
et al. previously showed that males have higher numbers of
IL-1β-producing monocytes in the blood compared to
females due to higher blood levels of testosterone [48].
Although LIF treatment prevented the increase in splenic
CXCL10 in young male rats, we did not observe a significant
change in splenic CXCL10 levels after a stroke or LIF treat-
ment among aged rats of either sex [36]. The return of
CXCL10+ splenocytes to the spleen after LIF treatment
may have obscured any changes in its intracellular expres-
sion. However, we did observe a significant upregulation in
the cytokine IL-3 and the IFNγ-inducible chemokine CXCL9
after MCAO+LIF treatment in aged animals of both sexes.
Although the higher levels of these cytokines might be
explained by a higher number of CXCL9-producing mono-
cytes and IL-3-producing T cells in the spleen, upregulation
of chemotactic cytokines may provide a beneficial role after
stroke by drawing inflammatory cells away from the brain
[49]. For instance, HUCB cells cause splenocytes to return
to the spleen after stroke via the secretion of potent chemo-
tactic cytokines [49, 50].
CXCL9, alternatively known as monokine induced by
IFNγ, is a potent inducer of T cell chemotaxis that signals
through CXCR3 [51]. Therefore, the increase in spleen size
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Figure 5: Sex and treatment change levels of IFNγ and IFNγ-inducible inflammatory mediators. (a) There was no significant difference in
IFNγ levels in the spleens of male or female rats after MCAO. n = 4 per treatment group for all groups except sham groups (n = 2). (b)
Relative levels of NO2
- were significantly higher among MCAO+PBS females (n = 7) compared to MCAO+PBS males (n = 10). LIF
significantly decreased NO2
- in the spleens of female rats (n = 8) compared to the MCAO+PBS female rats (n = 7; ∗p < 0:05). There was
no significant difference in relative NO2
- levels between MCAO+LIF male rats (n = 6) and MCAO+PBS male rats. n = 5 for male sham
and n = 4 for female sham groups. (c) MCAO+LIF-treated female rats (n = 5) had significantly higher levels of IL-3 in the spleen
compared to MCAO+PBS females (n = 6; ∗∗p < 0:01) and MCAO+LIF males (n = 8; ∗∗∗p < 0:001). However, there were no differences
between MCAO+PBS males (n = 7) and MCAO+LIF males. n = 2 for male sham group and n = 5 for female sham group.
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observed after LIF treatment in both sexes might be the result
of CXCL9-mediated chemotaxis of T cells from the periph-
eral circulation back to the spleen. Little is known about the
role of IL-3 in ischemic stroke; however, it is produced by
activated CD4+/CD8+ T cells and has been implicated in
the development of neuroinflammatory conditions such as
multiple sclerosis [52, 53]. Although IL-3 is mainly a chemo-
tactic factor for eosinophils [54], it has also been shown to
regulate the expression of CXCL9 [55] and act synergistically
with the chemokine CXCL12 to promote T cell chemotaxis.
Notably, Renner et al. demonstrated that treatment with
anti-IL-3 antibodies decreased leukocytic infiltration among
patients with relapsing-remitting multiple sclerosis. Since
IL-3 is secreted by T cells [56], the higher level of IL-3 and
CXCL9 observed after LIF treatment could also be explained
by a higher number of T cells in the spleen.
The results of this study demonstrate the necessity of
using age-appropriate animal models that take sex as a bio-
logical variable into account. Preclinical and clinical studies
testing the efficacy of potential anti-inflammatory and neuro-
protective treatments for stroke demonstrate that certain
drugs are efficacious in male, but not female, patients and
vice versa. For instance, minocycline, an antibiotic and
poly-ADP ribose polymerase inhibitor, only demonstrated
neuroprotective efficacy in male mice after ischemic stroke,
but not ovariectomized female mice [57]. A subsequent clin-
ical study mirrored the sex-dependent effects of the initial
preclinical study; while male patients showed recovery after
minocycline administration, there was no observable effect
in female patients [58]. A clinical study using uric acid as a
neuroprotective agent against ischemic stroke is further evi-
dence of the need to take sex as a biological variable into
account when examining poststroke outcomes. While initial
results suggested that uric acid did not improve outcomes,
further analysis of the data showed that female patients expe-
rienced positive outcomes after treatment [59]. Our previous
study, which showed that aged female rats, but not aged male
rats, showed motor skill recovery after LIF treatment, further
demonstrates the need to examine neuroprotective therapeu-
tics in age-appropriate models of both sexes [38].
Although this study provided insight regarding the effect
of LIF on the poststroke immune response in aged male and
female animals, some limitations need to be discussed. While
western blot analysis and ELISA demonstrate relative
changes in levels of inflammatory mediators compared to
baseline (sham) and PBS treatment, it does not provide
inflammation on cell-specific level markers such as
CD11b/LIFR. Furthermore, western blots do not provide
information about which cell types are responsible for
expressing these mediators. Therefore, future studies using
flow cytometry and immunohistochemistry will be necessary
to confirm the anti-inflammatory mechanisms of LIF in aged
animals and determine which splenocyte populations are the
most responsive to LIF treatment.
5. Conclusion
Through these experiments, we have shown that LIF exerts
stronger anti-inflammatory effects on the poststroke splenic
response in aged female rats, but not male rats. We believe
these effects were due to the upregulation of chemotactic
cytokines as well as the downregulation of inflammatory
mediators such as NO and IL-1β in the splenocytes of aged
female rats. Future studies using flow cytometry will be used
to determine whether higher levels of cytokines such as
CXCL9 and IL-3 are due to higher numbers of T cells and
monocytes/macrophages with the spleen or higher produc-
tion by each cell.
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